CellaVision AB (publ) (STO: CEVI)

Market Cap	5.43B
Revenue (ttm)	737.16M
Net Income (ttm)	150.21M
Shares Out	23.85M
EPS (ttm)	6.30
PE Ratio	36.12
Forward PE	29.81
Dividend	2.25 (0.99%)
Ex-Dividend Date	May 6, 2024

Volume	10,780
Average Volume	15,166
Open	223.00
Previous Close	225.00
Day's Range	222.00 - 227.00
52-Week Range	185.20 - 302.00
Beta	1.22
RSI	58.48
Earnings Date	Feb 6, 2025

About CellaVision AB

CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally. The company provides CellaVision DM1200 and CellaVision DM9600, designs to automate and simplify the process of performing blood and body fluid differentials; CellaVision DC-1, an analyzer to enable low-volume hematology labs to implement CellaVisions digital methodology for performing blood cell; and DIFF-Line that automates and digitizes the process of analyzing peripheral blood smears. It also offers ...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1994
• Employees: 228
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: CEVI

Financial Performance

In 2023, CellaVision AB's revenue was 677.29 million, an increase of 5.94% compared to the previous year's 639.34 million. Earnings were 130.31 million, an increase of 10.12%.